Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Živana Težak"'
Publikováno v:
Personalized medicine. 7(5)
Personalized medicine has captured the attention of the public, including patients, healthcare providers, scientists, medical product manufacturers and many others. The US FDA will evaluate many of the products that will allow personalized medicine t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89496dc77560a14493977daa82e922d
https://pubmed.ncbi.nlm.nih.gov/29776248
https://pubmed.ncbi.nlm.nih.gov/29776248
Publikováno v:
Expert Review of Molecular Diagnostics. 15:33-40
The rapid emergence and clinical translation of novel high-throughput sequencing technologies created a need to clarify the regulatory pathway for the evaluation and authorization of these unique technologies. Recently, the US FDA authorized for mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b41874775aec289944acf447ecfd052
https://doi.org/10.1586/14737159.2015.979795
https://doi.org/10.1586/14737159.2015.979795
Autor:
Bing Zhang, Denise Hinton, Emily S. Boja, Živana Težak, Henry Rodriguez, Elaine Johanson, Pei Wang
Publikováno v:
Nature Medicine
To address a critical roadblock that can occur in translational and clinical research, the National Cancer Institute and the Food and Drug Administration, in coordination with the DREAM Challenges, are launching the first computational challenge usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb4e236d419240293c5f1951389d542
http://europepmc.org/articles/PMC6892367
http://europepmc.org/articles/PMC6892367
Autor:
Saeed A. Jortani, Penny Keller, Pothur R. Srinivas, N. Leigh Anderson, Emily S. Boja, Amir Rahbar, Živana Težak, Robert Rivers, Henry Rodriguez, Elizabeth Mansfield, Andrew N. Hoofnagle, James C. Ritchie
Publikováno v:
Clinical Chemistry. 57:560-567
BACKGROUND Clinical proteomics presents great promise in biology and medicine because of its potential for improving our understanding of diseases at the molecular level and for detecting disease-related biomarkers for diagnosis, prognosis, and predi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5c4765b55df0acb5bd42aa040fe5f5
https://doi.org/10.1373/clinchem.2010.156034
https://doi.org/10.1373/clinchem.2010.156034
Autor:
Joshua LaBaer, David F. Ransohoff, Daniel C. Liebler, Ian Wright, Nader Rifai, Ann L. Oberg, Steven J. Skates, Grady Barnes, Elizabeth Mansfield, Emily S. Boja, Mitchell H. Gail, N. Leigh Anderson, Mehdi Mesri, Steven A. Carr, Michael A. Gillette, Živana Težak, Henry Rodriguez, Marina Kondratovich, Christopher R. Kinsinger
Protein biomarkers are needed to deepen our understanding of cancer biology and to improve our ability to diagnose, monitor and treat cancers. Important analytical and clinical hurdles must be overcome to allow the most promising protein biomarker ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad78a242409ce8d7d34c33738744bbd
Autor:
Joshua C. Kwekel, Francisco Martinez-Murillo, James C. Fuscoe, Reena Philip, Donna Roscoe, Ching-Wei Chang, Živana Težak, Yun Ge, Karen Bijwaard, Tao Han, Ying Chen
Publikováno v:
BMC Genomics
BMC Genomics, Vol 13, Iss 1, p 217 (2012)
BMC Genomics, Vol 13, Iss 1, p 217 (2012)
Background Genotyping assays often require substantial amounts of DNA. To overcome the problem of limiting amounts of available DNA, Whole Genome Amplification (WGA) methods have been developed. The multiple displacement amplification (MDA) method us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfe2577dace3c2b8dc7e94d01c96455f
https://pubmed.ncbi.nlm.nih.gov/22655855
https://pubmed.ncbi.nlm.nih.gov/22655855
Autor:
Mehdi Mesri, James Callaghan, Larry Kessler, Donna Roscoe, Steven J. Skates, Daniel C. Liebler, Henry Rodriguez, David F. Ransohoff, Tara Hiltke, Michail A. Alterman, Reena Philip, David G. Brown, Eugene Reilly, Paul Tempst, Steven A. Carr, Elizabeth Mansfield, Susan J. Fisher, Fred E. Regnier, Marina Kondratovich, Joshua D. Levin, Živana Težak, N. Leigh Anderson, Kellie Kelm, Christopher R. Kinsinger
Publikováno v:
Clinical chemistry. 56(2)
As a part of ongoing efforts of the NCI-FDA Interagency Oncology Task Force subcommittee on molecular diagnostics, members of the Clinical Proteomic Technology Assessment for Cancer program of the National Cancer Institute have submitted 2 protein-ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60ff81b7bf9617d6aa2443067b9382e0
https://pubmed.ncbi.nlm.nih.gov/20007858
https://pubmed.ncbi.nlm.nih.gov/20007858
Publikováno v:
Human Genomics
Human Genomics, Vol 2, Iss 4, Pp 236-243 (2006)
Human Genomics, Vol 2, Iss 4, Pp 236-243 (2006)
The US Food and Drug Administration (FDA) encourages the development of new technologies such as microarrays which may improve and streamline assessments of safety and the effectiveness of medical products for the benefit of public health. The FDA an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eab99240b79a5591112cbb3759969a95
https://doi.org/10.1186/1479-7364-2-4-236
https://doi.org/10.1186/1479-7364-2-4-236